Mikhail Blagosklonny Says Rapamycin Could Help In the Fight against Cancer and Aging in Humans

According to Mikhail Blagosklonny, a renowned researcher, there has been a belief that the process of aging was as a result of functional deterioration that is caused by the buildup or random molecular damage. Most scientists believe that it cannot be prevented. However, Mikhail is certain that by defying this dogma could bring new hope to cancer patients. He believes that rapamycin is the answer to the treatment of cancer and the aging process. According to Mikhail, when appropriate doses of rapamycin and other rapalogs are administered efficiently, they can extend the lifespan of cancer patients.

In 2006, it was concluded that the treatment was already permitted for clinical usage and it was availed in the various stores across the world for use. In addition to being used in the cancer treatment, rapamycin can be used in the treatment of cardiovascular illnesses, autoimmunity, and metabolic disorders as well as other ailments that are linked with aging. Rapamycin has been dubbed as the finest drug for use in the fight against various types’ cancer, senescence and cell aging in humans. Mikhail notes that rapamycin is nontoxic, and can be administered every day. Follow Mikhail on Google Scholar

More information on Mikhail

Mikhail Blagosklonny studies focus on the cancer treatment and aging. Mikhail is an outstanding researcher and has an MD in internal medicine and also a Ph.D. in experimental medicine and cardiology. Mikhail Blagosklonny research focuses on cancer, explicitly targeted at cancer therapies that may help in protecting the healthy body cells from damages. Mikhail has also conducted remarkable research and taken his time to study underlying processes that lead to aging. It also involves the research of drugs that may help in stopping, or just slowing down the aging process entirely.

Mikhail Blagosklonny began serving in the New York Medical College in 2002, where he was appointed the associate professor. Mikhail then went ahead to take the role as the senior scientist at Ordway Research Institute. He continued with his tenure at the institute until 2009 when he moved to Roswell Park Cancer Institute.

Mikhail is passionate about researching on various cancer topics. He also conducts research on biogerontology, the study of aging in humans. Mikhail Blagosklonny is renowned for formulating a theory in the possible role of TOR signaling in the fight against cancer and the adverse effects of aging. He has stated that rapamycin can be used to increase the lifespan of cancer patients. Rapamycin is used in cancer therapies to slow down the multiplication of cancer cells. Besides helping to reduce the spread of cancer cells, rapamycin can also assist in boosting the immune system of cancer patients. His outstanding research in this area earned him the recognition in longevity studies as an advocate for rapamycin.

View: https://www.researchgate.net/profile/Mikhail_Blagosklonny

Mikhail has passionately supported the use of rapamycin in longevity research. Mikhail is the editor-in-chief at Aging, a monthly open access medical journal that is peer reviewed. Impact journals publish the Aging medical journal, and it mainly focuses on research on senescence gerontology and the molecular mechanisms of aging.

Omar Boraie Established Genomic Science Chair at Rutgers Cancer Institute

Rutgers Cancer Institute, http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute, one of the major Cancer Institute based in New Jersey, got Omar Boraie Chair in specialized Genomic Science. It is considered that the establishment would help in developing precision medicine to address the various cancers. The chair is aimed to give best quality training and research to the scholars in developing effective treatment and medicine for cancers. It was named to Omar Boraie, the New Brunswick developer, as he donated $1.5 million to support the program. It was part of an “18 Chair Challenge” challenge by Rutgers University, as an anonymous donor contributes $1.5 million each for all the 18 chairs as each comes to $3 million.

The importance of the chair is in the wake of latest development and progress in precision medicine and treatment. The new technique ensures diagnosis and treatment of cancer at the genetic level. As this is giving individualized therapies for a better outcome, even former U.S. President Barack Obama endorsed the treatment method for better results in cancer cases. Rutgers Institute is the first institute in the country to use next-generation gene sequencing as a precision medicine approach to treating patients. The procedure is considered to be very effective for even rare cancers, where treatment is not much developed into an effective form. The development would also help to classify the cancers into subcategories according to characteristics with different genetics, to get better patient outcomes.

Omar Boraie said that he is very happy with the way the Institute is developing the precision medicine which gave positive results to patients with cancer no longer responsive. He also wonders what changes it makes when it applies to all cancer patients. He also said that he is extremely happy to be part of this great development program. Per the Newswise reports, Shridar Ganesan, MD, Ph.D., Principal Investigator of precision medicine in clinical trials and associate director for the translational science at Rutgers University Cancer Institute is named as the chairman.

With years of Oncology and research experience, Dr. Ganesan confirms that cancer is not a single disease but a collection of diseases with unique features for each. Rather than looking for the organ it affects, it is much better to do genomic analysis and classify it appropriately so that precise personalized medication can be applied. He said that he is honored to be named as the chair and hopes that the research and development would benefit even specific cancer patients with better outcomes.

Reference: https://www.bloomberg.com/profiles/companies/0601263D:US-boraie-development-llc